Guay D R, Awni W M, Halstenson C E, Kenny M T, Keane W F, Matzke G R
Drug Evaluation Unit, Hennepin County Medical Center, Minneapolis, Minnesota.
Antimicrob Agents Chemother. 1989 Nov;33(11):2012-5. doi: 10.1128/AAC.33.11.2012.
The pharmacokinetics of teicoplanin after single 6-mg/kg intravenous and intraperitoneal doses were studied in five noninfected patients undergoing continuous ambulatory peritoneal dialysis. Biological samples were assayed for teicoplanin content by a microbiological assay technique. Terminal disposition half-life (266.4 +/- 51.9 h [mean +/- standard error of the mean]) was prolonged and total body clearance (0.040 +/- 0.004 ml/min per kg) was reduced compared with values previously reported in subjects with normal renal function. The volume of distribution at steady state (1.15 +/- 0.19 liters/kg) was higher than values previously reported in subjects with normal renal function (0.56 to 0.72 liter/kg). Peritoneal dialysis clearance (0.007 +/- 0.001 ml/min per kg) accounted for only 16.1% of total body clearance. The absolute systemic bioavailability of teicoplanin after intraperitoneal administration was 81.5 +/- 10.7%.
在5例接受持续性非卧床腹膜透析的未感染患者中,研究了单次静脉注射和腹腔注射6mg/kg替考拉宁后的药代动力学。采用微生物测定技术测定生物样品中的替考拉宁含量。与先前报道的肾功能正常受试者的值相比,终末处置半衰期(266.4±51.9小时[平均值±平均标准误差])延长,全身清除率(0.040±0.004ml/分钟/千克)降低。稳态分布容积(1.15±0.19升/千克)高于先前报道的肾功能正常受试者的值(0.56至0.72升/千克)。腹膜透析清除率(0.007±0.001ml/分钟/千克)仅占全身清除率的16.1%。腹腔给药后替考拉宁的绝对系统生物利用度为81.5±10.7%。